Search PubMed⌕ Search

Biomedical subjects

M Asakawa

Publications and source records attributed to M Asakawa.

At least 127 records · Page 7Linked to original sources
PubMed1989

[Retrograde gonadal venography in patient with bilateral varicocele; a rare venous return via Santorini's plexus].

A 12-year-old boy was referred to our clinic because of microscopic hematuria. At out patient department, bilateral varicocele was found, but testes were within normal limit. Urinalysis showed microscopic hematuria, but other laboratory data were normal. Excretion urography was normal. Retrograde gonadal venogram showed a rara venous return via Santorini's plexus and lumbar veins. After varicocelectomy, urinalysis improved. It seemed that this condition was a new spermatic vein syndrome.

Child↗
PubMed1989

[Five cases of the double renal pelvis and ureter].

Five cases of the double renal pelvis and ureter were encountered among 340 cadavers for dissection practice. Number of minor calices and their surface area in these kidneys were calculated, and causal relationship to abnormal organogenesis was discussed. These 5 cases were formal exclusively in consist of males; 4 right sides and 1 left side, 2 complete duplications and 3 partial duplications. The 5 cases were divided into 2 groups by the number and surface area of minor calices in upper and lower pelvises as follows: 1) The number and surface area of minor calices in the upper pelvis and the lower pelvis were respectively equivalent to the mean value of those in one normal kidney (case 1). 2) The sum of the number and surface area of minor calices in the upper and those in the lower pelvises were equivalent to the mean value of those in one normal kidney (case 2-5). These cases give useful criteria for classification of the double renal pelvis and ureter.

Adult↗
PubMed1989

[Comparative clinical study of single and combination therapy of human lymphoblastoid interferon (HLBI) with 5-FU in the treatment of advanced renal cell carcinoma].

A clinical trial using human lymphoblastoid interferon (HLBI) was done on patients with advanced renal cell carcinoma to compare the efficacy of monotherapy with that of combined administration with a 5-fluorouracil (FU) agent. A total of 24 patients with definitely diagnosed advanced renal cell carcinoma were enrolled in either of the HLBI treatments. Principally, the daily intramuscular injection of 3 million units of HLBI was done for 4 consecutive days and thereafter followed by twice of weekly injections. The combined agent used in the present study was 300 or 600 mg of 5-fluorouracil agent given orally. The efficacy of HLBI was evaluated according to direct assessment standard of chemotherapy to a solid tumor expelled by the committee of Japanese health and welfare ministry. Of 11 patients who received monotherapy, 3 had a partial response rate of 27.3 percent. While only one of 13 patients having received combined HLBI administration with oral 5-FU tablets showed a partial response with a response rate of 7.7 percent. A total of 4 patients partially responded to either HLBI treatment with a subsequent response of 16.7 percent. Partial response implied reduction of lung metastatic foci in 3 patients and primary lesion in one patient. There was observed untoward fever-up in all patients with HLBI injections which was relieved with acquired tachyphylaxis owing to repeated injections. Otherwise minimal adverse effects were temporary elevation of liver transaminase in 4 and leucopenia in 2 patients during the HLBI treatment both of which eventually returned to the normal level without discontinuation of HLBI therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗
PubMed1988

[Intracavernous injection of vasoactive drugs for treating erectile impotence].

Intracavernous injection of various vasoactive drugs was performed in six erectile failure patients. The effects of each drug were evaluated in four grades: complete functional erection, incomplete functional erection, nonfunctional expansion and no effect. When papaverine hydrochloride (40 mg/ml) was administered, 4 of the 6 patients had nonfunctional expansion. By administering a mixture of 80 mg/ml papaverine hydrochloride with 1.0 mg/ml phentolamine mesylate, nonfunctional expansion was seen in four patients and incomplete functional erection in two patients. As for the effects of prostaglandin E1, incomplete functional erections were seen in all patients, while complete functional erection was seen in two patients. These findings indicated that the patients reacted differently to the same vasoactive drug, and that the papaverine and phentolamine mixture had a stronger effect than papaverine alone, while prostaglandin E1 had the strongest effect on erection. Intracavernous injection of the these drugs is useful for the treatment and differential diagnosis of impotence.

Aged↗
PubMed1988

[Transurethral resection of the prostatic gland (TUR-P) and incidental carcinoma].

During the four years between January, 1983 and December, 1986, transurethral resection of the prostatic gland (TUR-P) was performed on 108 patients with benign prostatic hypertrophy at Osaka Municipal Kita Citizen's Hospital. Histopathological examination of the transurethral resection specimens revealed 9 cases (8.3%) of incidental carcinoma. In this study, the average patient age, preoperative prostatic acid phosphatase (PAP) level and weight of resection specimens were compared for all 108 patients. For the 9 patients with incidental carcinoma, the clinical stage, histological grade and therapy were evaluated.

Acid Phosphatase↗
PubMed1988

Ofloxacin concentration in human benign prostatic tissue after oral administration.

The penetration of ofloxacin (OFLX) into prostatic tissue was examined on 11 patients with benign prostatic hypertrophy. OFLX was administered orally in a dose of 200 mg, three times one day before and twice on the day of operation. The blood sample was taken 30 minutes before operation and prostatic tissue specimens were collected during operation. The mean concentration of OFLX in prostatic tissue was 5.51 +/- 1.79 micrograms/g (mean +/- SD) and 5.36 +/- 1.28 micrograms/ml in serum. The mean ratio of these concentrations was 1.06 +/- 0.31 (range 0.55-1.54). These findings indicate that OFLX will be valuable against bacterial prostatitis.

Administration, Oral↗
PubMed1988

[Effect of metoprolol in patients with renal hypertension].

Eighteen patients with renal hypertension were treated with metoprolol (Seloken) for more than 3 months. Compared with the pretreatment value, the mean blood pressure decreased by 6.0, 11.2, 9.2 and 12.2 mmHg, after 2 weeks and 3, 6 and 12 months of treatment with metoprolol, respectively. All the differences observed were statistically significant (p less than 0.01). The blood pressure lowering effect of metoprolol was observed in 12 of the 17 patients (70.6%) examined. Decrease in plasma renin activity was seen in most of the responders. Although the number of patients was limited, the plasma level of metoprolol was also measured. The results indicated no sign of accumulation of metoprolol in the body. Moderate deterioration in renal function was observed in 1 patient but the treatment with metoprolol could be continued. Metoprolol administration had to be discontinued in 1 patient, who developed asthma. There were no other serious side effects.

Adult↗
PubMed1988

[Spontaneous peripelvic extravasation: a case report].

A case of spontaneous peripelvic extravasation is reported and discussed. A 41-year-old woman visited our hospital with the chief complaint of right flank pain. There was tenderness on the right side of the abdomen. Enhanced computed tomographic scan of the kidney showed peripelvic extravasation of right kidney. Single J ureteral catheter was inserted for 7 days. The excretory urogram obtained after its removal showed no extravasation.

Adult↗
PubMed1988

[Comparison of enoxacin, ofloxacin, and norfloxacin concentration in human benign prostatic tissue].

The penetration of pyridone-carboxylic acid drugs into benign prostatic tissue was examined. Twenty-nine patients were studied; 11 for ofloxacin (OFLX) 10 for enoxacin (ENX); and 8 for norfloxacin (NFLX). These drugs were administered orally at a dose of 200 mg three times one day before and twice on the day of operation. Blood sample was taken 30 min before operation and prostatic tissue sample was taken during operation. The mean prostatic concentration of ENX, OFLX and NFLX was 5.81 +/- 2.95 micrograms/g (range 2.99-7.92), 5.51 +/- 1.79 (3.62-7.19), and 4.42 +/- 1.94 (2.45-7.76), respectively. The mean serum concentration of ENX, OFLX and NFLX was 4.87 +/- 1.39 micrograms/ml (3.13-7.44), 5.36 +/- 1.28 (3.12-8.24), and 2.89 +/- 2.34 (0.87-8.33), respectively. The mean ratio of prostatic concentration/serum concentration of ENX, OFLX and NFLX was 1.21 +/- 0.63 (0.82-3.00), 1.06 +/- 0.31, (0.55-1.54) and 2.06 +/- 1.36 (0.93-4.26), respectively. Our findings suggested that the drugs ENX, OFLX and NFLX are useful for prostatic diseases, especially prostatitis.

Administration, Oral↗
PubMed1988

[Clinical efficacy of flucytosine on urinary candidiasis].

An antifungal agent (Flucytosine) was used to treat urinary candidiasis in 9 patients who had an indwelling catheter and developed fungal colony counts greater than 10(4). Among 9 patients with catheter drainage, urologic underlying diseases were benign prostatic hyperplasia in 7 and a neurogenic bladder in one patient all of whom had accompanied diabetes mellitus. Only one patient was supravesically diverted from the upper urinary tract through an indwelling catheter of bilateral ureterocutaneostomy after the removal of a tumorous bladder. All patients had previously received antimicrobials. Isolated strains of Candida were Candida albicans in 6, Candida tropicalis in 2, and Candida parapsilosis in one patient. Out of 9 patients having received daily administration of 1,500 mg Flucytosine for 2 weeks, 7 patients subsequently had no yield of fungal colony after the treatment. Minimum inhibitory concentration (MIC) of this agent was determined at the range of 0.1 to 0.2 microgram/ml in 5 patients with C. albicans and 0.2 microgram/ml in both patients with C. tropicalis. Otherwise, a high MIC of over 100 micrograms/ml indicating resistance to this agent was observed in only 2 patients with C. albicans and C. parapsilosis. Three of the 7 patients had recurrent urinary Candida infection even 2 weeks after the discontinuation of this antifungal therapy despite rapid and excellent eradication of urinary candidiasis. From these results, Flucytosine may be one of the most promising antifungal agent with a low MIC in the treatment of compromised urinary Candida infection and should be occasionally supplemented with a topical instillation of amphotericin B without any serious complication in the prevention of recurrence.

Aged↗
PubMed1988

[Enoxacin in the seminal fluid of prostatitis patients].

Ten patients with prostatitis were administered with Enoxacin (ENX), and the changes in its concentration in the seminal fluid were studied. For acute prostatitis patients, 600 mg/day of ENX was administered for 5 to 7 days, and for chronic prostatitis patients, 400 to 600 mg/day was administered for 7 to 17 days. Seminal fluid was obtained in the morning of examination and frozen until measurement. ENX was measured by the agar well method using E. coli. The concentration of ENX was 2.69 +/- 0.85 micrograms/ml and 3.98 +/- 2.49 micrograms/ml in acute and chronic prostatitis patients, respectively, and there was no significant difference between the two groups. When the dose and method of administration were compared, the mean ENX concentration was 3.65 micrograms/ml in the group administered 600 mg of ENX, while it was 2.60 micrograms/ml in the group administered 400 mg of ENX and not significantly different. When ENX was administered for 7 days, the mean ENX concentration was 3.13 micrograms/ml, but when it was administered for 14 days, it was 3.46 micrograms/ml slightly higher. These results indicate that since the concentration of ENX in the seminal fluid was higher than the minimum inhibitory concentration for the pathogens of prostatitis, ENX may be a clinically effective drug.

Adolescent↗